WO2015033224A3 - Méthodes de traitement du syndrome de l'x fragile et de troubles associés - Google Patents

Méthodes de traitement du syndrome de l'x fragile et de troubles associés Download PDF

Info

Publication number
WO2015033224A3
WO2015033224A3 PCT/IB2014/002398 IB2014002398W WO2015033224A3 WO 2015033224 A3 WO2015033224 A3 WO 2015033224A3 IB 2014002398 W IB2014002398 W IB 2014002398W WO 2015033224 A3 WO2015033224 A3 WO 2015033224A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
methods
related disorders
treating fragile
fragile
Prior art date
Application number
PCT/IB2014/002398
Other languages
English (en)
Other versions
WO2015033224A2 (fr
Inventor
Yaron DANIELY
Dalia Megiddo
Original Assignee
Alcobra Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Priority to JP2016539645A priority Critical patent/JP2016530291A/ja
Priority to KR1020167009040A priority patent/KR20160078956A/ko
Priority to AU2014316779A priority patent/AU2014316779A1/en
Priority to EA201690557A priority patent/EA201690557A1/ru
Priority to SG11201601605YA priority patent/SG11201601605YA/en
Application filed by Alcobra Ltd. filed Critical Alcobra Ltd.
Priority to US14/917,169 priority patent/US9851354B2/en
Priority to CA2922901A priority patent/CA2922901A1/fr
Priority to CN201480049671.5A priority patent/CN105517546A/zh
Priority to MX2016003006A priority patent/MX2016003006A/es
Priority to EP14830858.8A priority patent/EP3043792A2/fr
Publication of WO2015033224A2 publication Critical patent/WO2015033224A2/fr
Publication of WO2015033224A3 publication Critical patent/WO2015033224A3/fr
Priority to IL244343A priority patent/IL244343A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des méthodes d'atténuation d'un signe ou d'un symptôme du syndrome de l'X fragile et concerne des troubles tels que des troubles du spectre de l'autisme.
PCT/IB2014/002398 2013-09-09 2014-09-09 Méthodes de traitement du syndrome de l'x fragile et de troubles associés WO2015033224A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP14830858.8A EP3043792A2 (fr) 2013-09-09 2014-09-09 Méthodes de traitement du syndrome de l'x fragile et de troubles associés
CA2922901A CA2922901A1 (fr) 2013-09-09 2014-09-09 Methodes de traitement du syndrome de l'x fragile et de troubles associes
AU2014316779A AU2014316779A1 (en) 2013-09-09 2014-09-09 Methods of treating fragile X Syndrome and related disorders
EA201690557A EA201690557A1 (ru) 2013-09-09 2014-09-09 Способы лечения синдрома ломкой х-хромосомы и связанных расстройств
SG11201601605YA SG11201601605YA (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders
JP2016539645A JP2016530291A (ja) 2013-09-09 2014-09-09 脆弱ｘ症候群および関連障害の処置方法
US14/917,169 US9851354B2 (en) 2013-09-09 2014-09-09 Methods of treating fragile X syndrome and related disorders
KR1020167009040A KR20160078956A (ko) 2013-09-09 2014-09-09 취약 x 증후군 및 관련 장애의 치료 방법
CN201480049671.5A CN105517546A (zh) 2013-09-09 2014-09-09 治疗脆性x综合征及相关疾病的方法
MX2016003006A MX2016003006A (es) 2013-09-09 2014-09-09 Metodos para tratar el sindrome de x fragil y trastornos relacionados.
IL244343A IL244343A0 (en) 2013-09-09 2016-02-29 Methods for the treatment of fragile x syndrome and related disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US14/038,258 2013-09-26
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09

Publications (2)

Publication Number Publication Date
WO2015033224A2 WO2015033224A2 (fr) 2015-03-12
WO2015033224A3 true WO2015033224A3 (fr) 2015-07-02

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/054816 WO2015035402A1 (fr) 2013-09-09 2014-09-09 Procédés de détermination d'une réponse à un traitement
PCT/IB2014/002398 WO2015033224A2 (fr) 2013-09-09 2014-09-09 Méthodes de traitement du syndrome de l'x fragile et de troubles associés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/054816 WO2015035402A1 (fr) 2013-09-09 2014-09-09 Procédés de détermination d'une réponse à un traitement

Country Status (12)

Country Link
EP (2) EP3044589A1 (fr)
JP (2) JP2016530291A (fr)
KR (2) KR20160078956A (fr)
CN (2) CN105917225A (fr)
AU (2) AU2014316779A1 (fr)
CA (2) CA2922901A1 (fr)
EA (2) EA201690557A1 (fr)
IL (2) IL244343A0 (fr)
MX (2) MX2016003006A (fr)
SG (2) SG11201601830PA (fr)
TW (2) TW201606304A (fr)
WO (2) WO2015035402A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9673408B2 (en) * 2013-07-31 2017-06-06 Udc Ireland Limited Luminescent diazabenzimidazole carbene metal complexes
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
WO2019197632A1 (fr) * 2018-04-13 2019-10-17 Healx Limited Traitement du syndrome de l'x fragile
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
AU2019280980A1 (en) * 2018-06-07 2021-01-07 Ovid Therapeutics Inc. Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
JP7412583B2 (ja) * 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043507A2 (fr) * 2000-11-30 2002-06-06 The Health Research Institute Complements nutritifs et procedes de traitement de l'autisme et de prevention de l'apparition de l'autisme
WO2010150261A1 (fr) * 2009-06-25 2010-12-29 Alcobra Ltd. Procédé pour le traitement, l'atténuation de symptômes et le soulagement, l'amélioration et la prévention d'une maladie, d'un trouble ou d'un état cognitif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043507A2 (fr) * 2000-11-30 2002-06-06 The Health Research Institute Complements nutritifs et procedes de traitement de l'autisme et de prevention de l'apparition de l'autisme
WO2010150261A1 (fr) * 2009-06-25 2010-12-29 Alcobra Ltd. Procédé pour le traitement, l'atténuation de symptômes et le soulagement, l'amélioration et la prévention d'une maladie, d'un trouble ou d'un état cognitif

Also Published As

Publication number Publication date
IL244343A0 (en) 2016-04-21
EA201690559A1 (ru) 2016-08-31
SG11201601605YA (en) 2016-04-28
TW201605443A (zh) 2016-02-16
CA2922901A1 (fr) 2015-03-12
MX2016003002A (es) 2016-09-08
WO2015033224A2 (fr) 2015-03-12
AU2014315026A1 (en) 2016-03-24
KR20160086818A (ko) 2016-07-20
WO2015035402A1 (fr) 2015-03-12
CN105517546A (zh) 2016-04-20
CN105917225A (zh) 2016-08-31
SG11201601830PA (en) 2016-04-28
EA201690557A1 (ru) 2016-07-29
JP2016530291A (ja) 2016-09-29
MX2016003006A (es) 2016-06-10
EP3043792A2 (fr) 2016-07-20
KR20160078956A (ko) 2016-07-05
TW201606304A (zh) 2016-02-16
CA2923421A1 (fr) 2015-03-12
AU2014316779A1 (en) 2016-03-17
EP3044589A1 (fr) 2016-07-20
IL244453A0 (en) 2016-04-21
JP2016530536A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
WO2015033224A3 (fr) Méthodes de traitement du syndrome de l'x fragile et de troubles associés
IL276153B (en) c1-inh preparations and methods for preventing and treating disorders associated with c1 esterase inhibitor deficiency
EP3298480A4 (fr) Module d'affichage et procédé de fabrication associé
SG10202109444TA (en) Bendable glass stack assemblies, articles and methods of making the same
SG11201703813PA (en) Structured adsorbent beds, methods of producing the same and uses thereof
EP3057545A4 (fr) Méthodes et systèmes de traitement du syndrome des ovaires polykystiques
WO2014152157A8 (fr) Procédés et compositions pour la génération et l'utilisation d'anticorps spécifiques à une conformation
EP3548014A4 (fr) Kétamine pour le traitement de symptômes liés aux menstruations
EP3295284A4 (fr) Substrat tactile, dispositif d'affichage tactile doté de ce dernier, et procédé de fabrication associé
WO2014015210A3 (fr) Micro-organismes et procédés de conversion de glycérol en isoprène
WO2014121195A8 (fr) Cuves à réacteurs à flux et systèmes de réacteurs
EP3035992A4 (fr) Compositions, méthodes et systèmes de traitement des troubles de la peau
EP3041577A4 (fr) Traitement et prévention de l'autisme et des troubles du spectre autistique
EP3083555A4 (fr) Procédés de diazotisation de 2,5 dichloroanilines
WO2016167944A3 (fr) Compositions et méthodes permettant de traiter l'hyperperméabilité intestinale
WO2015092810A3 (fr) Forme amorphe d'idélalisib
EP3249450A4 (fr) Substrat, réseau et panneau d'affichage
EP2961420A4 (fr) Méthodes et compositions de prévention ou de traitement du syndrome de barth
EP3359486A4 (fr) Générateur d'ozone par plasma à froid
EP2953993A4 (fr) Polymères, substrats, procédés de fabrication de ceux-ci, et dispositifs comprenant ceux-ci
WO2014204303A3 (fr) Procédés de prévention de l'agrégation de composants viraux
WO2016109002A3 (fr) Méthodes et compositions pour le traitement de troubles liés à l'irradiation
EP3631385A4 (fr) Agencement de chargement de train
EP3063016A4 (fr) Articles de métal écroui à froid comprenant des particules de phosphore luminescentes, leurs procédés de formation, et leurs procédés d'authentification
PL3038980T3 (pl) Nadające się do obróbki cieplnej lakierowane podłoże szklane i/lub sposób jego wykonania

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 244343

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2922901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14917169

Country of ref document: US

Ref document number: MX/A/2016/003006

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016539645

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014316779

Country of ref document: AU

Date of ref document: 20140909

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016005095

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2014830858

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014830858

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167009040

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201690557

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14830858

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016005095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160309